Ballicules.com

Levofloxacin

LEVAQUIN

Pronunciation: lee-voe-FLOX-a-sin

Levofloxacin ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Levofloxacin ballicule
Levofloxacin LEVAQUIN mascot mnemonic cartoon
Visual mnemonic: Levofloxacin mascot
“Leave a flock of cinnamon queens”

What it isFluoroquinolone inhibiting topoisomerase IV and DNA gyrase; pneumonia, urinary and intra-abdominal infection.

Why this oneIt bridges respiratory and urinary niches: better pneumococcal coverage than ciprofloxacin, with urinary penetration moxifloxacin lacks.

What limits itTendon rupture, neuropathy, CNS effects and QT prolongation. Cations bind it; renally adjusted.

Levofloxacin molecular structure (skeletal formula)
Molecular structure: Levofloxacin

FDA-approved for

FDA label

BOXED WARNING Disabling/potentially irreversible reactions — tendinitis/tendon rupture, peripheral neuropathy, CNS effects; may exacerbate myasthenia gravis (avoid). Reserve for no-alternative use in uncomplicated UTI, acute bacterial exacerbation of chronic bronchitis, and acute bacterial sinusitis.
FDA dosingPopulationStartTargetMax
Nosocomial pneumoniaAdults (CLcr ≥50)750 mg QD750 mg QD ×7–14d750 mg QD
Community-acquired pneumoniaAdults500 mg QD ×7–14d or 750 mg QD ×5d500–750 mg QD750 mg QD
Complicated skin/skin-structure infectionAdults750 mg QD ×7–14d750 mg QD750 mg QD
Uncomplicated skin/skin-structure infectionAdults500 mg QD ×7–10d500 mg QD500 mg QD
Chronic bacterial prostatitisAdults500 mg QD ×28d500 mg QD500 mg QD
Complicated UTI / acute pyelonephritisAdults750 mg QD ×5d or 250 mg QD ×10d250–750 mg QD750 mg QD
Uncomplicated UTIAdults250 mg QD ×3d250 mg QD250 mg QD
Acute bacterial exacerbation of chronic bronchitisAdults500 mg QD ×7d500 mg QD500 mg QD
Acute bacterial sinusitisAdults750 mg QD ×5d or 500 mg QD ×10–14d500–750 mg QD750 mg QD
Inhalational anthrax (post-exposure) / plagueAdults & peds ≥50 kg (≥6 mo)500 mg q24h500 mg q24h (anthrax 60d; plague 10–14d)500 mg q24h
Inhalational anthrax (post-exposure) / plaguePeds 30–<50 kg250 mg q12h250 mg q12h250 mg q12h

Renal Adjust for CLcr <50 mL/min (750 mg regimen → 750 mg q48h; 500 mg regimen → 500 then 250 mg q24–48h; 250 mg regimen → 250 mg q48h per CLcr 20–49, 10–19, HD/CAPD). No adjustment if CLcr ≥50.

Hepatic Undefined

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy Human data have not identified drug-associated risk; not teratogenic in animals.

Lactation Present in human milk; breastfeeding not recommended during and for 2 days after last dose (may pump and discard).

Cost

Levofloxacin (LEVAQUIN)
What pharmacies pay · NADAC 9/30/26
Strength#/mogeneric $CostPlus
250 mgtab30 qd$3.26/mooffered
500 mgtab30 qd$4/mooffered
750 mgtab30 qd$7.76/mooffered
250 mg/10 mLsolper unitnot offered
5 mg/mLinjper unitnot offered
25 mg/mLinjper unitnot offered

Generic entryBy 2023

⚠ BOXED WARNINGS

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades3 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryC

Defining liabilityTendon/aortic injury, dysglycemia and CNS effects; QT or CYP1A2 risk varies by agent.

Open Levofloxacin in the interactive console ↗

Memory aids: interaction avatars

Levofloxacin OAT substrate avatar mnemonic
OAT substrate

Open Levofloxacin in the interactive console ↗